Search for:

Search Medicine or Company Name Search Full Document

Advanced Search

sanofi-aventis
1 Onslow Street, Guildford, Surrey, GU1 4YS, UK Telephone: +44 (0)1483 505 515 Fax: +44 (0)1483 535 432 Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com Need to contact this company?

Summary of Product Characteristics last updated on the eMC: 25/02/2010

SPC	Maalox Plus Tablets

Table of Contents

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
LEGAL STATUS

Go to top of the page

1. NAME OF THE MEDICINAL PRODUCT

Maalox Plus Tablets

Go to top of the page

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Aluminium hydroxide gel (dried)	BP	200mg
Magnesium hydroxide	BP	200mg
Simeticone		25mg

Go to top of the page

3. PHARMACEUTICAL FORM

Tablets.

Go to top of the page

4. CLINICAL PARTICULARS

Go to top of the page

4.1 Therapeutic indications

The symptomatic relief of:

a. Dyspepsia

b. Heartburn

c. Flatulence

Go to top of the page

4.2 Posology and method of administration

Route of administration: Oral

Adults (including elderly persons): 1-2 tablets well chewed, four times a day, taken twenty minutes to one hour after meals and at bedtime, or as required.

Children: Not recommended

Go to top of the page

4.3 Contraindications

Should not be used in patients who are severely debilitated or suffering from kidney failure.

Go to top of the page

4.4 Special warnings and precautions for use

In patients with renal impairment, plasma levels of both aluminium and magnesium increase. In these patients, a long-term exposure to high doses of aluminium and magnesium salts may lead to dementia, microcytic anemia.

Aluminum hydroxide may be unsafe in patients with porphyria undergoing hemodialysis.

Go to top of the page

4.5 Interaction with other medicinal products and other forms of interaction

Maalox Plus should not be taken simultaneously with other medicines as they may interfere with their absorption if taken within 1 hour.

Aluminum hydroxide and citrates may result in increased aluminum levels, especially in patients with renal impairment.

Go to top of the page

4.6 Pregnancy and lactation

The safety of Maalox Plus Tablets in pregnancy has not been established..

Magnesium is considered as compatible with lactation

Go to top of the page

4.7 Effects on ability to drive and use machines

None stated.

Go to top of the page

4.8 Undesirable effects

Gastrointestinal side effects are uncommon.

Go to top of the page

4.9 Overdose

Serious symptoms are unlikely following overdosage.

Treatment of magnesium overdose: consider administration of IV Calcium Gluconate, rehydration and forced diuresis. In case of renal deficiency, haemodialysis or peritoneal dialysis is necessary.

Go to top of the page

5. PHARMACOLOGICAL PROPERTIES

Go to top of the page

5.1 Pharmacodynamic properties

Dried aluminium hydroxide gel - antacid

Magnesium hydroxide - antacid

Simeticone - Antifoaming agent/antiflatulent

The antacids are balanced such that gastrointestinal side effects (constipation and diarrhoea) are minimal.

Go to top of the page

5.2 Pharmacokinetic properties

None stated

Go to top of the page